The Effect of Medication Reminder Technology on Medication Adherence and Hypertension Outcomes

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2013 by Purdue University
Sponsor:
Information provided by (Responsible Party):
Alan Zillich Lab, Purdue University
ClinicalTrials.gov Identifier:
NCT01755312
First received: December 18, 2012
Last updated: June 12, 2013
Last verified: June 2013
  Purpose

This study to evaluates how a med reminder affects the patient's ability to take medications as prescribed


Condition Intervention
Medication Adherence
Blood Pressure
Device: Medication reminder

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: The Effect of Medication Reminder Technology on Medication Adherence and Hypertension

Resource links provided by NLM:


Further study details as provided by Purdue University:

Primary Outcome Measures:
  • self-reported medication adherence using the Morisky 8-Item Medication Adherence Scale(MMAS-8) tool [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • systolic blood pressure in mmHg using a valid automated device [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 240
Study Start Date: June 2013
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: medication reminder
medication reminder
Device: Medication reminder
Medication reminder
Placebo Comparator: Placebo
Placebo

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • poor medication adherence
  • high blood pressure

Exclusion Criteria:

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01755312

Contacts
Contact: Alan Zilllich, PharmD 317-613-2315 ext 320 azillich@purdue.edu

Locations
United States, Indiana
Purdue University Recruiting
West Lafayette, Indiana, United States, 47906
Contact: Alan Zillich, PharmD    317-613-2315 ext 320    azillich@purdue.edu   
Principal Investigator: Alan Zillich, PharmD         
Sponsors and Collaborators
Purdue University
  More Information

No publications provided

Responsible Party: Alan Zillich Lab, Associate Professor Pharmacy Practice, Purdue University
ClinicalTrials.gov Identifier: NCT01755312     History of Changes
Other Study ID Numbers: 2r44ago39178-02 (1208012596)
Study First Received: December 18, 2012
Last Updated: June 12, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on July 31, 2014